To include your compound in the COVID-19 Resource Center, submit it here.

Product Development
Three CEPI-funded vaccines secure additional manufacturing resources

Three CEPI-funded vaccines secured additional manufacturing resources Thursday in a trio of announcements that included the first advanced market commitment from the ACT ...

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus ...

Daily Chart: COVID-19 trials with near-term milestones

At least 232 clinical trials of therapeutics and vaccines for

Read the full 104 word article

Politics, Policy & Law
Legislation creating provisional approval pathway introduced in U.S. Senate

Sens. Mike Braun (R-Ind.), Lisa Murkowski (R-Alaska), and Martha McSally (R-Ariz.) Wednesday introduced legislation that would create a provisional approval pathway for

AstraZeneca adds RNA-modifying targets to oncology pipeline via Accent deal

Less then two months after its series B round, Accent has added $55 million to its balance sheet after partnering with AstraZeneca to co-develop up to three of its cancer programs ...

TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

Growing enthusiasm around next-generation checkpoint target TIGIT fueled a £56 million ($70 million) raise for Mereo, which plans to start a Phase Ib trial of etigilimab in 4Q20. ...

With $85M series B, Athira seeks to recover neuronal health in Alzheimer’s patients

Athira’s crossover-laden $85 million series B round will fund the start of a pivotal trial this year of an Alzheimer’s disease therapy that the company thinks could not only slow ...

BioCentury ISSN 1097-7201